These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 8251323)

  • 1. Hyperlipidemia in childhood nephrotic syndrome.
    Thabet MA; Salcedo JR; Chan JC
    Pediatr Nephrol; 1993 Oct; 7(5):559-66. PubMed ID: 8251323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The hyperlipidemia of the nephrotic syndrome.
    Appel GB; Valeri A; Appel AS; Blum C
    Am J Med; 1989 Nov; 87(5N):45N-50N. PubMed ID: 2486547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism.
    Vega GL; Grundy SM
    Kidney Int; 1988 Jun; 33(6):1160-8. PubMed ID: 3165483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Disturbances of lipid metabolism during nephrotic syndrome: physiopathology and treatment].
    Moulin B; Ollier J; Olmer M
    Nephrologie; 1992; 13(5):193-9. PubMed ID: 1470293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment.
    Wheeler DC; Bernard DB
    Am J Kidney Dis; 1994 Mar; 23(3):331-46. PubMed ID: 8128933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity.
    Appel GB; Blum CB; Chien S; Kunis CL; Appel AS
    N Engl J Med; 1985 Jun; 312(24):1544-8. PubMed ID: 3858668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenesis of hyperlipidemia in the nephrotic syndrome.
    Attman PO; Alaupovic P
    Am J Nephrol; 1990; 10 Suppl 1():69-75. PubMed ID: 2256478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nephrotic hyperlipidemia: primary abnormalities in both lipoprotein catabolism and synthesis.
    Kaysen GA
    Miner Electrolyte Metab; 1992; 18(2-5):212-6. PubMed ID: 1465061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and management of hyperlipidemia of the nephrotic syndrome.
    Grundy SM; Vega GL
    Am J Med; 1989 Nov; 87(5N):3N-11N. PubMed ID: 2486542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid changes in the nephrotic syndrome: new insights into pathomechanisms and treatment.
    D'Amico G
    Klin Wochenschr; 1991 Sep; 69(13):618-22. PubMed ID: 1753684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-denisty lipoprotein receptor deficiencies in nephrotic syndrome.
    Vaziri ND; Liang KH
    Circulation; 2004 Jul; 110(4):419-25. PubMed ID: 15262831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteinuria, hyperlipidemia, and the kidney.
    Hutchison FN
    Miner Electrolyte Metab; 1993; 19(3):127-36. PubMed ID: 8232099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypocholesterolemic effect of spirulina in patients with hyperlipidemic nephrotic syndrome.
    Samuels R; Mani UV; Iyer UM; Nayak US
    J Med Food; 2002; 5(2):91-6. PubMed ID: 12487756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the aggressive management of hyperlipidemia in nephrotic syndrome mandatory?
    Keane WF; St Peter JV; Kasiske BL
    Kidney Int Suppl; 1992 Oct; 38():S134-41. PubMed ID: 1405364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should hyperlipidemia in children with the nephrotic syndrome be treated?
    Querfeld U
    Pediatr Nephrol; 1999 Jan; 13(1):77-84. PubMed ID: 10100296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.
    Vaziri ND
    Kidney Int; 2016 Jul; 90(1):41-52. PubMed ID: 27165836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism of low density lipoproteins in nephrotic dyslipidemia: comparison of hypercholesterolemia alone and combined hyperlipidemia.
    Vega GL; Toto RD; Grundy SM
    Kidney Int; 1995 Feb; 47(2):579-86. PubMed ID: 7723244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction in proteinuria attenuates hyperlipidemia in the nephrotic syndrome.
    Kaysen GA; Davies RW
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S75-9. PubMed ID: 16989070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-density lipoprotein metabolism in the nephrotic syndrome.
    Warwick GL; Caslake MJ; Boulton-Jones JM; Dagen M; Packard CJ; Shepherd J
    Metabolism; 1990 Feb; 39(2):187-92. PubMed ID: 2299990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis.
    de Sain-van der Velden MG; Kaysen GA; Barrett HA; Stellaard F; Gadellaa MM; Voorbij HA; Reijngoud DJ; Rabelink TJ
    Kidney Int; 1998 Apr; 53(4):994-1001. PubMed ID: 9551409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.